Redefining Development Speed: What Infectious Disease Programs Can Teach Us About R&D Agility

Session details:

With decades of executive experience leading global development programs at Roche, AbbVie, and now Atea, Dr. Janet Hammond shares practical, proven strategies to accelerate drug development - without compromising scientific integrity. Drawing from her work on antiviral and infectious disease programs, including efforts to reshape hepatitis C treatment, this talk offers biotech leaders and BD professionals a look inside the operational mindset and clinical design choices that can create real speed in high-stakes development environments.

Attendees will learn:

• How infectious disease programs manage urgency and rigor - and what other therapeutic areas can adapt
• The operational frameworks Atea is applying to move next-gen HCV treatments forward quickly
• What biotechs should prioritize early in development to streamline regulatory engagement and clinical trial design
• Why cross-functional team design, clear endpoints, and built-in flexibility are central to development acceleration
• Lessons learned from global development across large pharma and small biotech environments